PIK3CB and melanoma: Regarding ongoing clinical trials, a phase I/II trial (NCT03131908) is investigating the selective PI3K-beta inhibitor GSK2636771 in combination with pembrolizumab in patients with refractory metastatic PTEN-loss melanoma.